Collegium Pharmaceutical, Inc. (COLL) Cash and securities
- Total cash · latest quarter (USD): Value $129.47M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $129.47M | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $129.47M + $0.00 ≈ $129.47M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 129.47M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 0.00 USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Cash and current securities | 129.47M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $129.47M | (m) | $129.47M | $0.00 | (m) |
| 2026-03-31 | $421.75M | (m) | $268.65M | $153.10M | (m) |
| 2025-12-31 | $386.68M | (m) | $231.25M | $155.43M | (m) |
| 2025-09-30 | $285.86M | (m) | $150.10M | $135.77M | (m) |
| 2025-06-30 | $222.15M | (m) | $117.35M | $104.81M | (m) |
| 2025-03-31 | $197.77M | (m) | $96.19M | $101.58M | (m) |
| 2024-12-31 | $162.76M | (m) | $70.56M | $92.20M | (m) |
| 2024-09-30 | $119.96M | (m) | $38.96M | $81.00M | (m) |
| 2024-06-30 | $271.63M | (m) | $172.89M | $98.74M | (m) |
| 2024-03-31 | $318.05M | (m) | $228.61M | $89.44M | (m) |
| 2023-12-31 | $310.55M | (m) | $238.95M | $71.60M | (m) |
| 2023-09-30 | $304.56M | (m) | $258.53M | $46.03M | (m) |
| 2023-06-30 | $325.47M | (m) | $283.75M | $41.72M | (m) |
| 2023-03-31 | (m) | (m) | $269.48M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $173.69M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $134.13M | (m) | (m) |
| 2022-06-30 | (m) | (m) | $122.72M | (m) | (m) |
| 2022-03-31 | (m) | (m) | $106.70M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $186.43M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $193.24M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $202.77M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $182.79M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $174.12M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $165.42M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $145.68M | (m) | (m) |
| 2020-03-31 | (m) | (m) | $116.18M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $170.02M | (m) | (m) |
| 2019-09-30 | (m) | (m) | $153.84M | (m) | (m) |
| 2019-06-30 | (m) | (m) | $148.71M | (m) | (m) |
| 2019-03-31 | (m) | (m) | $134.91M | (m) | (m) |
| 2018-12-31 | (m) | (m) | $146.63M | (m) | (m) |
| 2018-09-30 | (m) | (m) | $139.79M | (m) | (m) |
| 2018-06-30 | (m) | (m) | $133.75M | (m) | (m) |
| 2018-03-31 | (m) | (m) | $128.25M | (m) | (m) |
| 2017-12-31 | (m) | (m) | $118.70M | (m) | (m) |
| 2017-09-30 | (m) | (m) | $107.61M | (m) | (m) |
| 2017-06-30 | (m) | (m) | $111.21M | (m) | (m) |
| 2017-03-31 | (m) | (m) | $129.56M | (m) | (m) |
| 2016-12-31 | (m) | (m) | $153.22M | (m) | (m) |
| 2016-09-30 | (m) | (m) | $91.03M | (m) | (m) |
| 2016-06-30 | (m) | (m) | $110.75M | (m) | (m) |
| 2016-03-31 | (m) | (m) | $134.73M | (m) | (m) |
| 2015-12-31 | (m) | (m) | $95.70M | (m) | (m) |
| 2015-09-30 | (m) | (m) | $105.46M | (m) | (m) |
| 2015-06-30 | (m) | (m) | $112.41M | (m) | (m) |
| 2015-03-31 | (m) | (m) | $44.99M | (m) | (m) |
| 2014-12-31 | (m) | (m) | $1.63M | (m) | (m) |
| 2014-09-30 | (m) | (m) | $4.18M | (m) | (m) |
| 2014-06-30 | (m) | (m) | $2.59M | (m) | (m) |
| 2014-03-31 | (m) | (m) | $4.81M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $7.55M | (m) | (m) |
| 2012-12-31 | (m) | (m) | $11.94M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |